Replies to post #167658 on Biotech Values

[DewDiligence]

ABBV/ENTA—[Mostly agree but] I do think they will do better than you predict in genotype 1b without ribavirin… The new [phase-2] data being presented in GT1b with 2 DAAs also suggests a third DAA will push results to >95% in naives and probably >90% in tx experienced.

I hope you’re right, of course; if ABBV/ENTA can attain those numbers without ribavirin, ENTA investors are going to do even better than I’ve been expecting.

I don’t think ABBV would run ribavirin-free arms [in PEARL-2/3/4] if they thought it would cost them 10+% in SVR.

Disagree here; I think the PEARL-2/3/4 trials had to include ribavirin-free arms to find out if ribavirin is needed because the SAPHIRE-1/2 trials contain no such arms.